Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    21639810 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Placebo;   Drug: Dacarbazine
2 Unknown  A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Ipilimumab and Fotemustine

Indicates status has not been verified in more than two years